TD Cowen Maintains Buy on PTC Therapeutics, Raises Price Target to $95

Benzinga · 2d ago
TD Cowen analyst Joseph Thome maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $90 to $95.